Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598593 | 1.00 | AR (0.60) | ARNOTUM | |
| SCHEMBL4871562 | 1.00 | AR (0.60) | ARNOTUM | |
| SCHEMBL3606814 | 0.89 | AR (0.64) | AR | |
| SCHEMBL29952767 | 0.86 | NOTUM (0.57) | NOTUM | |
| SCHEMBL29950827 | 0.86 | NOTUM (0.57) | NOTUM | |
| SCHEMBL15330773 | 0.86 | NOTUM (0.57) | NOTUM | |
| SCHEMBL4879566 | 0.83 | NPSR1 (0.52) | AR | |
| SCHEMBL4877817 | 0.83 | ALDH1A1 (0.58) | AR | |
| SCHEMBL3596357 | 0.82 | AR (0.67) | AR | |
| SCHEMBL27616353 | 0.81 | AR (0.65) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20090042857-A1 | Novel Pharmaceutical | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1987827-A1 | NOVEL PHARMACEUTICAL | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | AR 1/4885NOTUM 3786/4885 |
| US-20090042857-A1 | Novel Pharmaceutical | AR, NR5A1, NR5A2 | AR 1/4885NOTUM 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.